StreetInsider.com News Articles

Prime Drink Group launches CA$4M subscription receipt financing

Thu, 15 Oct 2026 19:56:15 -0400

Prime Drink Group Corp. (CSE: PRME) has announced a proposed private placement financing of subscription receipts targeting maximum gross proceeds of CA$4.0 million, with a CA$2.5 million lead order already received from an institutional investor, according to a company statement.

Each subscription receipt will convert into one common share at CA$0.10 and one common share purchase warrant, exercisable at CA$0.11 per share for two years. Proceeds will be held in escrow until the company completes its proposed acquisition of Prime Capital Investments Inc. and a strategic partnership with GefCo, part of Les Entreprises du Groupe Geloso. Net proceeds are intended to

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Thu, 15 Oct 2026 19:56:00 -0400

MONTREAL--(BUSINESS WIRE)-- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate gross proceeds of CA$4.0 million (the “Financing”) and that it has received a CA$2.5 million lead order from an institutional investor in connection with the Financing.

Each subscription receipt will entitle the holder thereof, upon satisfaction of the Escrow Release Conditions (as defined below), and without payment of any additional consideration or further action on the part of the holder, to receive one common share of the Company (a “Common Share”)

Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units

Thu, 15 Oct 2026 19:56:00 -0400

Prime Medicine (PRME) Reiterated at Market Outperform by Citizens

Tue, 06 Oct 2026 05:35:01 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $7.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented, "Prime Medicine successfully dosed a first patient with H1069Q-mutated Wilson disease (WD) with LNP-delivered Prime Editor PM577a. The asset has been granted rare pediatric disease designation. The update is significant as it marks PRME's official transition to clinical stage and affirms the company's projection for potential proof-of-concept data in early 2027. We maintain our Market Outperform rating and $7 DCF-derived PT."

For an analyst ratings summary and ratings history on Prime Medicine click here. For more ratings news on Prime

Prime Medicine doses first patient in Wilson disease gene editing trial

Mon, 05 Oct 2026 08:00:17 -0400

Prime Medicine, Inc. (Nasdaq: PRME) announced that the first patient has been dosed in its global Phase 1/2 clinical trial of PM577a, an investigational in vivo Prime Editing therapy for H1069Q-mutated Wilson disease. The company also announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to PM577 for Wilson disease.

The open-label, first-in-human study is designed to evaluate the safety, tolerability, and preliminary clinical efficacy of ascending doses of PM577a in adults and adolescents with Wilson disease carrying at least one H1069Q allele in the ATP7B gene. The trial will initially enroll adults who are clinically

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Mon, 05 Oct 2026 08:00:00 -0400

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a --

-- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North
America and Europe‌ --

-- PM577 granted Rare Pediatric Disease Designation by the U.S. FDA --

-- Initial clinical data expected in 2027 --

CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

Mon, 05 Oct 2026 08:00:00 -0400

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a --

-- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North
America and Europe‌ --

-- PM577 granted Rare Pediatric Disease Designation by the U.S. FDA --

-- Initial clinical data expected in 2027 --

CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative

Prime Drink Group Announces Filing of Annual and Interim Financial Statements and Anticipated CTO Revocation

Wed, 30 Sep 2026 10:54:00 -0400

MONTREAL, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has filed today its audited annual financial statements for the year ended March 31, 2026 and its interim financial statements for the three months ended June 30, 2026, together with the related management's discussion and analysis and Chief Executive Officer and Chief Financial Officer certificates (collectively the “Financial Filings”). Copies of the Financial Filings are available under the Company’s SEDAR+ profile at www.sedarplus.ca.

With the completion of the Financial Filings, the Company has

Prime Drink Group Announces Filing of Annual and Interim Financial Statements and Anticipated CTO Revocation

Wed, 30 Sep 2026 10:54:00 -0400

With the completion of the Financial Filings, the Company has

Prime Medicine (PRME) Reiterated at Market Outperform by Citizens - Still a Leader in Prime Editing

Mon, 28 Sep 2026 04:33:03 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $7.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented, "Prime Medicine is the foundational leader in Prime Editing (PE) and it has developed significant capabilities that 1) extend the reach of gene editing beyond the current targets of the first-generation gene-editing companies; and 2) provide lower risk for unwanted genomic alterations. Importantly, PRME also developed PASSIGE, a tool to efficiently insert larger genes into DNA at a precise location. PRME has two INDs open in large liverbased indications, Wilson’s Disease (WD) with PM577a and Alpha-1-antitrypsin deficiency (AATD) with PM647),

Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as PM647 Application Cleared

Fri, 25 Sep 2026 04:14:45 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $7.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented, "Prime Medicine announced that the U.S. FDA cleared the IND application for PM647 in Alpha-1 Antitrypsin Deficiency (AATD). Recall, PRME announced a favorable resolution of its arbitration proceeding with Beam Therapeutics (BEAM, NC), affirming Prime's rights to PM647 in AATD. Prime will initially enroll patients with pulmonary-only disease to achieve proof-of-concept, and we anticipate first data in 2027. We maintain our Market Outperform rating and $7 DCF derived price target ahead of enrollment of the AATD study."

For an analyst ratings

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 24 Sep 2026 17:30:00 -0400

MONTREAL, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14, August 27 and September 10, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 24 Sep 2026 17:30:00 -0400

Prime Medicine stock surges on FDA IND clearance

Thu, 24 Sep 2026 16:38:50 -0400

Investing.com -- Prime Medicine Inc (NASDAQ:PRME) shares gained over 12% in after-hours trading Thursday following the FDA's clearance of the company's Investigational New Drug application for PM647, an in vivo gene editing therapy for Alpha-1 Antitrypsin Deficiency.

The FDA clearance allows PM647 to proceed to clinical study in the United States, where approximately 100,000 people carry the PiZZ genotype that the therapy is designed to correct. Initial clinical data is expected in 2027.

PM647 is designed to correct the

Prime Medicine stock surges on FDA IND clearance

Thu, 24 Sep 2026 16:38:50 -0400

PM647 is designed to correct the

FDA clears Prime Medicine's IND for AATD gene editing therapy

Thu, 24 Sep 2026 16:01:20 -0400

Prime Medicine, Inc. (Nasdaq: PRME) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for PM647, an investigational in vivo Prime Editor targeting Alpha-1 Antitrypsin Deficiency (AATD).

The clearance allows PM647 to advance into clinical study in the United States, where approximately 100,000 people carry the PiZZ genotype the therapy is designed to correct. Across the United States and Europe, approximately 200,000 people are estimated to carry the PiZZ genotype.

PM647 is designed to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, the most common cause of AATD. The therapy uses the same liver-directed

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Thu, 24 Sep 2026 16:01:00 -0400

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a --

-- Initial clinical data expected in 2027 --

CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables PM647 to

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Thu, 24 Sep 2026 16:01:00 -0400

-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a --

-- Initial clinical data expected in 2027 --

Prime Drink Group Finalizes Settlement With Creditors

Mon, 21 Sep 2026 07:30:00 -0400

MONTREAL, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has finalized and agreed to settlement terms between Prime, Roynat Inc. (“Roynat”), and Financement Agricole Canada (“FAC” together with Roynat, the “Creditors”) and has completed a one-time cash payment of $1,010,000 to the Creditors (the “Settlement Payment”). As a result of the Settlement Payment, the Company has been released by the Creditors from all guarantees made by the Company related to loans extended to Triani Canada Inc., which represented potential exposure to the Company

Prime Drink Group Finalizes Settlement With Creditors

Mon, 21 Sep 2026 07:30:00 -0400

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 10 Sep 2026 17:30:00 -0400

MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14 and August 27, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 10 Sep 2026 17:30:00 -0400

Prime Drink Group closes first tranche of private placement at $1.35M

Thu, 10 Sep 2026 07:30:29 -0400

Prime Drink Group Corp. (CSE: PRME) completed the first closing of a non-brokered private placement, raising gross proceeds of $1,349,200, according to a press release from the Montreal-based company.

The company issued 26,984,000 common shares and 26,984,000 warrants. Each warrant allows the holder to purchase one common share at $0.10 for a period of two years from the issuance date.

The securities are subject to a hold period of four months and one day from issuance under Canadian securities laws. The offering remains subject to final approval from the Canadian Securities Exchange and other applicable regulatory bodies.

Prime Drink Group said it intends

Prime Drink Group Announces First Closing of Private Placement

Thu, 10 Sep 2026 07:30:00 -0400

MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a first closing of its previously announced non-brokered private placement offering of units of the Company (the “Unit Offering”) for gross proceeds of $1,349,200. As a result, the Company issued 26,984,000 common shares in the capital of the Company (the “Common Shares”) and 26,984,000 warrants. Each warrant entitles the holder to purchase one Common Share at a price of $0.10 per share for a period of two (2) years from the issuance date.

The securities underlying the

Prime Drink Group Announces First Closing of Private Placement

Thu, 10 Sep 2026 07:30:00 -0400

The securities underlying the